Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., J. Medical Virology, July 9, 2020, doi:10.1002/jmv.26286 (preprint 6/29) (Peer Reviewed)
Chronic treatment with hydroxych loroquine and SARS-CoV-2 infection
Chronic treatment with HC
Q provides protection against COVID, odds ratio 0.51 (0.37-0.70).
The actual benefit is likely to be larger becasue research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall. Ferri et al. show OR 4.42, p
<0.001 , which is the observed real-world risk, taking into account factors such as these patients potentially being more careful to avoid exposure.
COVID-19 case, ↓47.1%, p<0.0001
(odds ratio converted to relative risk)
Please send us corrections, updates, or comments.